Physician profile
Adelina Hung
NPI 1326300120
$18,439.06
in general payments reported to CMS, 2019-2025
22 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $86.19 · 2022: $210 · 2023: $590 · 2024: $1,207 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $3,770 · Travel and Lodging: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,345.00 |
| Food and Beverage | $3,770.26 |
| Travel and Lodging | $903.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,613.73 | 2022-2025 | |
| Madrigal Pharmaceuticals | $4,241.53 | 2025 | Rezdiffra |
| Arcutis Biotherapeutics, INC. | $2,711.65 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $708.60 | 2019-2025 | |
| Lilly USA, LLC | $469.32 | 2023-2025 | Omvoh, Ebglyss, Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $356.37 | 2022-2025 | Entyvio |
| Abbvie INC. | $326.98 | 2023-2025 | |
| Janssen Biotech, INC. | $187.58 | 2023-2025 | Tremfya, Stelara |
| Ucb, INC. | $90.34 | 2022 | |
| Pfizer INC. | $86.57 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $86.19 | 2021 | |
| Gilead Sciences, INC. | $74.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.17 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $72.00 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $63.22 | 2025 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $60.10 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $57.02 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $55.46 | 2024 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $52.51 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $26.05 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $20.07 | 2024 | Voquezna |
| Echosens North America, INC. | $5.67 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelina Hung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.